Acute Liver Failure Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | RHEACELL, Versantis, Martin Pharmaceuticals, Grifols Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Liver Failure pipeline constitutes 5+ key companies continuously working towards developing 5+ Acute Liver Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Liver Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Acute Liver Failure Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/acute-liver-failure-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Liver Failure Market.

Some of the key takeaways from the Acute Liver Failure Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Acute Liver Failure treatment therapies with a considerable amount of success over the years.

*
Acute Liver Failure companies working in the treatment market are Promthera Biosciences, Akaza Biosciences, Grifols Therapeutics, GENFIT, Yaqrit, GENFI, Cellaion, Grifols Therapeutics, and others, are developing therapies for the Acute Liver Failure treatment

*
Emerging Acute Liver Failure therapies in the different phases of clinical trials are- Hepastem, TAK-242, ALBUTINE (Albumin 5%), Nitazoxanide, TAK-242, VS-01, HepaStem, SMT + PE-A 5%, and others are expected to have a significant impact on the Acute Liver Failure market in the coming years.

*
In February 2025, Genfit Biopharma announced that alongside the expected Phase II results from the UNVEIL-IT trial assessing VS-01 in the second half of this year, it also plans to share up to three additional clinical datasets from its ACLF pipeline by the end of 2025.

*
The US FDA has granted Orphan Drug Designation (ODD) to VS-01 for the treatment of ACLF.

*
In March 2024, HepaRegeniX GmbH, a clinical-stage company focused on developing regenerative therapies for acute and chronic liver diseases, has published clinical and preclinical findings on its first-in-class MKK4 inhibitor, HRX-215, in the journal Cell. The study, available online (DOI: 10.1016/j.cell.2024.02.023), highlights HRX-215's ability to significantly enhance liver regeneration and prevent liver failure in preclinical models. Additionally, a first-in-human trial demonstrated its safety and tolerability. HRX-215 is a small molecule inhibitor targeting Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Acute Liver Failure Overview

Acute-on-Chronic Liver Failure (ACLF) is a serious condition in which a person with pre-existing chronic liver disease experiences sudden and severe worsening of liver function. This rapid decline often leads to complications such as jaundice, bleeding, infections, or multi-organ failure. ACLF has a high risk of mortality and typically requires urgent medical care, with liver transplantation being a potential life-saving option in severe cases.

Get a Free Sample PDF Report to know more about Acute Liver Failure Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-liver-failure-pipeline-insight [https://www.delveinsight.com/report-store/acute-liver-failure-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Acute Liver Failure Drugs Under Different Phases of Clinical Development Include:

*
Hepastem: Promthera Biosciences

*
TAK-242: Akaza Biosciences

*
ALBUTINE (Albumin 5%): Grifols Therapeutics

*
Nitazoxanide: GENFIT

*
TAK-242: Yaqrit

*
VS-01: GENFIT

*
HepaStem: Cellaion

*
SMT + PE-A 5%: Grifols Therapeutics

Acute Liver Failure Route of Administration

Acute Liver Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical.

*
Molecule Type

Acute Liver Failure Molecule Type

Acute Liver Failure Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Acute Liver Failure Pipeline Therapeutics Assessment

*
Acute Liver Failure Assessment by Product Type

*
Acute Liver Failure By Stage and Product Type

*
Acute Liver Failure Assessment by Route of Administration

*
Acute Liver Failure By Stage and Route of Administration

*
Acute Liver Failure Assessment by Molecule Type

*
Acute Liver Failure by Stage and Molecule Type

DelveInsight's Acute Liver Failure Report covers around 5+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Acute Liver Failure product details are provided in the report. Download the Acute Liver Failure pipeline report to learn more about the emerging Acute Liver Failure therapies [https://www.delveinsight.com/sample-request/acute-liver-failure-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Acute Liver Failure Therapeutics Market include:

Key companies developing therapies for Acute Liver Failure are - RHEACELL, Versantis, Martin Pharmaceuticals, Grifols Therapeutics, Promethera Biosciences, GENFIT, Akaza Bioscience, Cipla, and others.

Acute Liver Failure Pipeline Analysis:

The Acute Liver Failure pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Acute Liver Failure with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Liver Failure Treatment.

*
Acute Liver Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Acute Liver Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Liver Failure market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Liver Failure drugs and therapies [https://www.delveinsight.com/sample-request/acute-liver-failure-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acute Liver Failure Pipeline Market Drivers

*
Increase in the prevalence of liver diseases, increase in the number of research and development activities are some of the important factors that are fueling the Acute Liver Failure Market.

Acute Liver Failure Pipeline Market Barriers

*
However, side-effects associated with the treatment of Acute Liver Failure (ACLF), high cost associated with the treatment and other factors are creating obstacles in the Acute Liver Failure Market growth.

Scope of Acute Liver Failure Pipeline Drug Insight

*
Coverage: Global

*
Key Acute Liver Failure Companies: Promthera Biosciences, Akaza Biosciences, Grifols Therapeutics, GENFIT, Yaqrit, GENFI, Cellaion, Grifols Therapeutics, and others

*
Key Acute Liver Failure Therapies: Hepastem, TAK-242, ALBUTINE (Albumin 5%), Nitazoxanide, TAK-242, VS-01, HepaStem, SMT + PE-A 5%, and others

*
Acute Liver Failure Therapeutic Assessment: Acute Liver Failure current marketed and Acute Liver Failure emerging therapies

*
Acute Liver Failure Market Dynamics: Acute Liver Failure market drivers and Acute Liver Failure market barriers

Request for Sample PDF Report for Acute Liver Failure Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/acute-liver-failure-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Acute Liver Failure Report Introduction

2. Acute Liver Failure Executive Summary

3. Acute Liver Failure Overview

4. Acute Liver Failure- Analytical Perspective In-depth Commercial Assessment

5. Acute Liver Failure Pipeline Therapeutics

6. Acute Liver Failure Late Stage Products (Phase II/III)

7. Acute Liver Failure Mid Stage Products (Phase II)

8. Acute Liver Failure Early Stage Products (Phase I)

9. Acute Liver Failure Preclinical Stage Products

10. Acute Liver Failure Therapeutics Assessment

11. Acute Liver Failure Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Liver Failure Key Companies

14. Acute Liver Failure Key Products

15. Acute Liver Failure Unmet Needs

16 . Acute Liver Failure Market Drivers and Barriers

17. Acute Liver Failure Future Perspectives and Conclusion

18. Acute Liver Failure Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-liver-failure-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-rheacell-versantis-martin-pharmaceuticals-grifols-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.